Impaired unsaturated fatty acid elongation alters mitochondrial function and accelerates metabolic dysfunction-associated steatohepatitis progression.
Fiche publication
Date publication
octobre 2024
Journal
Metabolism: clinical and experimental
Auteurs
Membres identifiés du Cancéropôle Est :
Dr RIALLAND Mickaël, Dr PAIS DE BARROS Jean-Paul, Pr MASSON David
Tous les auteurs :
Vouilloz A, Bourgeois T, Diedisheim M, Pilot T, Jalil A, Le Guern N, Bergas V, Rohmer N, Castelli F, Leleu D, Varin A, de Barros JP, Degrace P, Rialland M, Blériot C, Venteclef N, Thomas C, Masson D
Lien Pubmed
Résumé
Although qualitative and quantitative alterations in liver Polyunsaturated Fatty Acids (PUFAs) are observed in MASH in humans, a causal relationship of PUFAs biosynthetic pathways is yet to be clarified. ELOVL5, an essential enzyme in PUFA elongation regulates hepatic triglyceride metabolism. Nonetheless, the long-term consequences of elongase disruption, particularly in murine models of MASH, have not been evaluated.
Mots clés
Cardiolipins, ELOVL5, MASH, MASLD, PUFAs, Steatosis
Référence
Metabolism. 2024 10 23;:156051